Stanford School of Medicine
Program in Epithelial Biology In the Department of Dermatology

Daria Mochly-Rosen

Email:
Profile: http://med.stanford.edu/profiles/Daria_Mochly-Rosen/

Alternate Contact:
Name: Jean Kavanagh
Title: Admistrative Associate
Email: jeankav@stanford.edu
Phone: 650 725 5088

Academic Appointments
Appointment
Organization
Professor
Member
Graduate & Fellowship Program Affiliations
 
Administrative Appointments
Title
Organization
Start Year
End Year
Professor
Department of Chemical and Systems Biology
2001
-
Chief
Division of Chemical Biology
2001
2002
Member
Neuroscience Institute at Stanford
2002
-
Chair
Department of Molecular Pharmacology
2002
2006
Professor, by courtesy
Department of Neurosurgery
2004
-
7  appointments: view full list
Professional Education
Degree
Awarding Institution
Field of Study
Year of Graduation
Ph.D.
Weizmann Institute, Israel
Chemical Immunology
1983
B.S.
Tel Aviv University, Israel
Life Sciences
1977
Postdoctoral Advisees
Grant Budas, Eric Churchill, Suresh Palaniyandi, Xin Qi, Nir Qvit
Web Site Links
Research/Lab website:   Mochly-Rosen Lab Site
Research Interests

We are studying the mechanism of protein kinase C-mediated signal transduction in several disease models. Based on our recent data, we proposed a working hypothesis that activated PKC isozymes bind to intracellular receptor proteins located at different subcellular sites, and that these receptors differentially bind specific PKC isozymes. Evidence was obtained for the presence of intracellular receptor proteins that bind activated PKC. Binding of PKC to these proteins was concentration-dependent, saturable and specific, suggesting that these binding proteins are receptors for activated C-kinase, or "RACKs".

We have characterized and cloned several RACKs and identified domains in different PKC isozymes that are required for the specific association with these RACKs; these domains are distinct from the substrate binding site on PKC. On the basis of this information, together with computer modeling of crystal structures of the interacting proteins, we have identified novel isozyme-selective inhibitors that inhibit translocation and the consequent function of individual PKC isozymes. These inhibitors are fragments of PKC or RACKs that have 'dominant negative' activities on PKC binding to RACKs and on their activities, in vivo. In addition, we prepared synthetic peptides corresponding to the binding sites in PKC and RACKs. We are currently determining the effects of these isozyme-selective translocation inhibitors on a number of PKC-mediated cell functions in normal and diseased heart. These include cardiac and smooth muscle cell contraction, gene expression, hypertrophy, and response to and protection from ischemic insult.

Publications
  • Qi X, Inagaki K, Sobel RA, Mochly-Rosen D "Sustained pharmacological inhibition of deltaPKC protects against hypertensive encephalopathy through prevention of blood-brain barrier breakdown in rats." J Clin Invest 2008; 118: 1: 173-82 More »
  • Kaneda H, Ikeno F, Inagaki K, Mochly-Rosen D "Preserved coronary endothelial function by inhibition of delta protein kinase C in a porcine acute myocardial infarction model." Int J Cardiol 2008; More »
  • Shimohata T, Zhao H, Sung JH, Sun G, Mochly-Rosen D, Steinberg GK "Suppression of deltaPKC activation after focal cerebral ischemia contributes to the protective effect of hypothermia." J Cereb Blood Flow Metab 2007; More »
  • Bright R, Steinberg GK, Mochly-Rosen D "deltaPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo." Brain Res 2007; More »
  • Siwko S, Mochly-Rosen D "Use of a novel method to find substrates of protein kinase C delta identifies M2 pyruvate kinase." Int J Biochem Cell Biol 2007; More »
148 publications:   view full list

Institution Links:

Footer Links: